Biomet Spine Introduces Living Cell Product
Tycho supernova xray. Source: Wikimedia Commons and NASA/CXC/Rutgers/J.Warren & J.Hughes et al. Biomet Spine introduced Cellentra VCBM (Viable Cell Bone Matrix), the third cell spine market entrant, at this year’s annual meeting of the North American Spine Society (NASS) in Dallas, Texas. The introduction of Cellentra was Biomet’s twelfth new product introduction in the past 12 months.
“Cellentra™ VCBM offers the complete bone healing triad, including viable osteogenic cells, verified osteoinductivity, and an osteoconductive scaffold” said Jennifer Grasso, Director of Marketing at Biomet Spine & Bone Healing Technologies. “Every lot of Cellentra™ VCBM is proven to contain at least 250, 000 viable cells per cc, including mesenchymal stem cells (MSCs), osteoprogenitor cells and pre-osteoblasts.”
Grasso further defined the new product. “The demineralized component of Cellentra™ VCBM provides additional inherent growth factors, including BMP-2, 4, 7, VEGF, TGF- β, PDGF, IGF-1 and FGF.” She said that the cancellous bone matrix of Cellentra™ VCBM, offers an interconnected trabecular structure for optimal osteoconductivity.
Biomet officials believe that the introduction of Cellentra™ VCBM complements Biomet Spine’s line of Biologics and Implantable Stimulation products which includes the Indux™ Cortical Strip and SpF® Implantable Spine Fusion Stimulator. Jennifer Grasso went on to state: Biomet, located in Warsaw, Indiana, was founded in 1977. It presently distributes products in 90 countries.
